Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

flutiform® pMDI tolerability


flutiform® pMDI has demonstrated a good safety and tolerability profile over 12 months.1*

flutiform® pMDI has a similar tolerability profile to fluticasone propionate/ salmeterol pMDI†2 and budesonide/ formoterol DPI.‡3

*Open-label study: Patients ≥12 years treated with flutiform® pMDI 50/5 μg or 125/5 μg two puffs b.i.d for 6 or 12 months.1


Randomised, open-label, 12-week study in patients ≥18 years (flutiform® pMDI 50/5 μg or 125/5 μg two puffs b.i.d. vs fluticasone propionate/ salmeterol pMDI 50/25 μg or 125/25 μg two puffs b.i.d).2


Randomised, double-blind, double-dummy 12-week study (flutiform® pMDI 125/5 μg two puffs b.i.d. vs budesonide/ formoterol 200/6 μg two puffs b.i.d).3


Abbreviations: b.i.d, twice-daily; DPI, dry powder inhaler; pMDI, pressurised metered-dose inhaler

lady and sunshine

Safety Profile4


Adverse events which have been associated with flutiform® pMDI during clinical development, listed by system organ class, are available in the flutiform® Prescribing Information. None of the adverse events have been classed as very common (1/10) or common (≥1/100 and <1/10).

View Prescribing Information

Abbreviation: pMDI, pressurised metered-dose inhaler


  1. Mansur AH, et al. J Aerosol Med Pulm Drug Deliv. 2012:26(4):190-199.
  2. Bodzenta-Lukaszyk A, et al. BMC Pulm Med. 2011;11:28.
  3. Bodzenta-Lukaszyk A, et al. J Asthma. 2012;49:1060-1070.
  4. flutiform® SmPC. Last updated 13 April 2022. Accessed 5 September 2022.

Join our mailing list!


Join your colleagues and sign up for the latest news on the management of asthma and flutiform® pMDI straight to your inbox.

Subscribe here

Abbreviation: pMDI: pressurised metered-dose inhaler

Pen on paper

®: FLUTIFORM is the Trademark of Jagotec AG used under licence by Mundipharma.

®: The ‘lung’ logo, is a Registered Trademark of Mundipharma.